Atlas Trials

Osimertinib as First-line Therapy for Patients With Late-stage Lung Cancer

Clinical trial NCT03460275 · UNKNOWN

Trial details

NCT number
NCT03460275
Sponsor
Sun Yat-sen University
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Non-small Cell Lung Cancer
Start date
2018-02-26
Primary completion
2020-12-01
Enrollment
100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.